Natco Pharma to make, sell bio-generics

19 Oct 2011 Evaluate

Drugmaker Natco Pharma has signed a pact with Switzerland-based Chemo Sa Lugano to source and sell bio-generic products in India and other Asian countries. The pact allows Natco to source four monoclonal antibodies (mAbs) from the Mabxience, a unit of Chemo Sa Lugano, and use them for manufacturing and commercialising finished dosages. Of the four products, three are cancer treatment molecules and one is used in the treatment of auto-immune diseases. Monoclonal antibodies is a highly innovative market globally valued at about Rs 17,250 crore ($35 billion) with insignificant presence of generic products. With the product combinations chosen by Natco, the mAb initiative is likely to be completed over a period of 24-36 months.

Natco Pharma Share Price

833.85 -6.00 (-0.71%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×